Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 18/20 | 0.67 |
| ▸ | DDB1 | Q16531 | 11/20 | 0.67 |
| ▸ | TNF | P01375 | 2/20 | 0.65 |
| ▸ | IKZF3 | Q9UKT9 | 2/20 | 0.65 |
| ▸ | IL1B | P01584 | 1/20 | 0.65 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.65 |
| ▸ | IKZF1 | Q13422 | 1/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.58 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.58 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.58 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.58 |
| ▸ | TSHR | P16473 | 1/20 | 0.58 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.58 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.49 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24379097 | 0.88 | CRBN (0.69) | CRBNDDB1TNFIKZF3IL1B | |
| SCHEMBL25650349 | 0.87 | CRBN (0.67) | CRBNDDB1TNFIKZF3IL1B | |
| SCHEMBL25650287 | 0.87 | CRBN (0.67) | CRBNDDB1TNFIKZF3IL1B | |
| SCHEMBL19451377 | 0.86 | CRBN (0.66) | CRBNDDB1TNFIKZF3IL1B | |
| SCHEMBL25275500 | 0.85 | CRBN (0.61) | CRBNDDB1TNFIKZF3IL1B | |
| SCHEMBL12041884 | 0.85 | CRBN (0.67) | CRBNDDB1TNFIKZF3IL1B | |
| SCHEMBL24745183 | 0.85 | CRBN (0.65) | CRBNDDB1TNFIKZF3IL1B | |
| SCHEMBL15439893 | 0.85 | CRBN (0.67) | CRBNDDB1TNFIKZF3IL1B | |
| SCHEMBL25271938 | 0.84 | CRBN (0.62) | CRBNDDB1TNFIKZF3IL1B | |
| SCHEMBL25223335 | 0.84 | CRBN (0.62) | CRBNDDB1TNFIKZF3IL1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117586340-A | Bifunctional compound for targeted degradation of METTL3, pharmaceutical composition and application | 中国科学院上海药物研究所 | 2024-02-23 | — | — | CN | disclosed |
| WO-2024035626-A1 | HALOPHTHALIMIDE COMPOUNDS AND METHODS OF USE AGAINST TBI, INFLAMMATORY DISORDER, AUTOIMMUNE DISORDER, NEURODEGENERATIVE DISEASE OR VIRAL INFECTION | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2024-02-15 | — | — | WO | disclosed |
| EP-4180432-A1 | COMPOUND HAVING BTK KINASE DEGRADING ACTIVITY, AND PREPARATION METHOD AND PHARMACEUTICAL USE THEREFOR | Sichuan Haisco Pharmaceutical Co., Ltd. (CN) | 2023-05-17 | — | — | EP | disclosed |
| WO-2022111526-A1 | BENZENE RING DERIVATIVE, AND COMPOSITION AND PHARMACEUTICAL USE THEREOF | 四川海思科制药有限公司 | 2022-06-02 | — | — | WO | disclosed |
| WO-2022007903-A1 | COMPOUND CAPABLE OF INHIBITING AND DEGRADING ANDROGEN RECEPTORS, AND PHARMACEUTICAL COMPOSITIONS AND PHARMACEUTICAL USES THEREOF | 四川海思科制药有限公司 | 2022-01-13 | — | — | WO | disclosed |
| WO-2022007824-A1 | COMPOUND HAVING BTK KINASE DEGRADING ACTIVITY, AND PREPARATION METHOD AND PHARMACEUTICAL USE THEREFOR | 四川海思科制药有限公司 | 2022-01-13 | — | — | WO | disclosed |
| WO-2020239103-A1 | BTK INHIBITOR RING DERIVATIVE, PREPARATION METHOD THEREFOR AND PHARMACEUTICAL APPLICATION THEREOF | 四川海思科制药有限公司 | 2020-12-03 | — | — | WO | disclosed |